Rhythm Pharmaceuticals, Inc.
RYTM
Rank in Stocks
#2996
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Share Price
$88.85
Market Cap
$6.12B
Change (1 day)
-1.50%
Change (1 year)
-17.08%
Country
US
Trade Rhythm Pharmaceuticals, Inc. (RYTM)
Category
Healthcare
Stock price history for Rhythm Pharmaceuticals, Inc. (RYTM)
Highest end of day price: $89.53 on 2026-10-01
Lowest end of day price: $24.67 on 2017-10-01
Lowest end of day price: $24.67 on 2017-10-01
Stock price history of Rhythm Pharmaceuticals, Inc. from 2017 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -8.85% |
| 2025 | 91.54% |
| 2024 | 34.76% |
| 2023 | 48.81% |
| 2022 | 174.77% |
| 2021 | -64.82% |
| 2020 | 24.27% |
| 2019 | -12.59% |
| 2018 | -6.07% |
| 2017 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $516.91 | 21.26% |
US
|
|
| $247.62 | 800.77% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $879.36 | 5.34% |
NL
|
|
| $752.87 | 7.40% |
CH
|
